MRK · Merck & Co., Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Research
our published analysis of this company
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Animal Health Sales | $1.79B | FY2026 Q1 | +12.8% |
|
|
|||
| CAPVAXIVE Sales | $142M | FY2026 Q1 | +32.7% |
|
|
|||
| GARDASIL/GARDASIL 9 Sales | $1.07B | FY2026 Q1 | -19.4% |
|
|
|||
| WINREVAIR Sales | $0.34B | FY2026 Q1 | +9.3% |
|
|
|||
| KEYTRUDA/KEYTRUDA QLEX Sales | $31.7B | Full-Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRK
this stock
Merck & Co., Inc.
|
$320.56B | +25.5% | +1.4% | 36.6 | 1.2% |
|
LLY
ELI LILLY & Co
|
$1.08T | +7.1% | +44.7% | 40.8 | 1.1% |
|
JNJ
Johnson & Johnson
|
$616.50B | +24.5% | +6.0% | 29.7 | 1.1% |
|
ABBV
AbbVie Inc.
|
$454.79B | +10.7% | +8.6% | 126.8 | 1.3% |
|
NVS
Novartis AG
|
$296.80B | +16.7% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRK | -0.7% | +0.5% | +8.4% | +1.3% | +25.5% |
| SPY | +1.1% | +0.3% | +8.2% | +0.0% | +9.6% |
| vs SPY | -1.8% | +0.2% | +0.2% | +1.3% | +16.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.